Legal & General Group Plc Lowers Stock Holdings in Masimo Corporation $MASI

Legal & General Group Plc trimmed its holdings in shares of Masimo Corporation (NASDAQ:MASI) by 10.0% in the 4th quarter, Holdings Channel.com reports. The firm owned 92,436 shares of the medical equipment provider’s stock after selling 10,241 shares during the period. Legal & General Group Plc’s holdings in Masimo were worth $12,022,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in MASI. Royal Bank of Canada lifted its holdings in shares of Masimo by 44.5% during the first quarter. Royal Bank of Canada now owns 43,884 shares of the medical equipment provider’s stock valued at $7,311,000 after purchasing an additional 13,513 shares during the last quarter. AQR Capital Management LLC increased its position in shares of Masimo by 136.5% during the first quarter. AQR Capital Management LLC now owns 8,142 shares of the medical equipment provider’s stock valued at $1,305,000 after acquiring an additional 4,700 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Masimo by 0.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 11,371 shares of the medical equipment provider’s stock valued at $1,894,000 after acquiring an additional 66 shares in the last quarter. Dynamic Technology Lab Private Ltd bought a new stake in shares of Masimo during the first quarter valued at approximately $220,000. Finally, Jones Financial Companies Lllp increased its position in shares of Masimo by 1,267.1% during the first quarter. Jones Financial Companies Lllp now owns 2,201 shares of the medical equipment provider’s stock valued at $367,000 after acquiring an additional 2,040 shares in the last quarter. 85.96% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on MASI shares. Raymond James Financial downgraded shares of Masimo from an “outperform” rating to a “market perform” rating in a research report on Friday, March 27th. Wells Fargo & Company raised shares of Masimo to a “hold” rating in a research report on Wednesday, March 18th. Stifel Nicolaus set a $180.00 price target on shares of Masimo in a research report on Tuesday, February 17th. Piper Sandler downgraded shares of Masimo from an “overweight” rating to a “hold” rating and set a $180.00 price target for the company. in a research report on Tuesday, February 17th. Finally, BTIG Research downgraded shares of Masimo from a “buy” rating to a “neutral” rating in a research report on Wednesday, February 18th. Nine analysts have rated the stock with a Hold rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $180.40.

Masimo Trading Up 0.0%

Shares of MASI stock opened at $178.78 on Thursday. Masimo Corporation has a 12-month low of $125.94 and a 12-month high of $179.00. The company has a current ratio of 2.68, a quick ratio of 1.45 and a debt-to-equity ratio of 0.56. The firm’s 50 day moving average is $178.43 and its 200 day moving average is $158.99. The stock has a market capitalization of $9.36 billion, a P/E ratio of -16.96, a P/E/G ratio of 1.81 and a beta of 1.11.

Masimo Profile

Masimo (NASDAQ: MASI) is a global medical technology company specializing in noninvasive monitoring solutions. The company’s flagship technology, Masimo SET® (Signal Extraction Technology), enhances the accuracy of pulse oximetry in challenging clinical conditions. Beyond pulse oximetry, Masimo’s portfolio extends to brain function monitoring, regional oximetry, and acoustic respiration rate monitoring, serving critical, acute, and ambulatory care settings.

In addition to its core monitoring technologies, Masimo offers a range of patient cables, sensors, and connectivity platforms designed to integrate with hospital information systems and remote monitoring applications.